Display Settings:

Format

Send to:

Choose Destination
    Med Microbiol Immunol. 2005 Aug;194(4):201-6. Epub 2005 Apr 21.

    Efficacy of AIDS vaccine strategies in nonhuman primates.

    Source

    Department of Molecular and Medical Virology, Ruhr-University Bochum, 44780 Bochum, Germany. klaus.ueberla@ruhr-uni-bochum.de

    Abstract

    Since only a limited number of vaccines can be tested for efficacy in phase 3 studies in humans, a filter is needed allowing selection of the most promising ones. Although differences between HIV infection in humans and simian immunodeficiency virus infection in nonhuman primates (NHP) might limit the predictive value of these models, comparative efficacy studies in NHPs could facilitate ranking of vaccine candidates. While various forms of protein vaccines failed to induce consistent protection, live-attenuated vaccines, DNA vaccines and viral vector vaccines provided various levels of protection in NHPs. However, variability in the experimental models limits the conclusions that can be drawn with respect to the relative efficacy of vaccines not tested in the same experiment. Therefore, better standardization is an urgent necessity in order to exploit the full potential of nonhuman primate models in AIDS vaccine development.

    PMID:
    15843997
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Springer

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk